COSCIENS Biopharma Inc. (CSCID)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 6M 12M 18M Q1 '19: 2.3M Q2 '19: 2.3M Q3 '19: 1.9M Q4 '19: 532K Q1 '20: 1.6M Q2 '20: 1.5M Q3 '20: 1.3M Q4 '20: 3.7M Q1 '21: 4.2M Q2 '21: 5.7M Q3 '21: 6.7M Q4 '21: 5.3M Q1 '22: 5.1M Q2 '22: 3.3M Q3 '22: 4.1M Q4 '22: 14.6M Q1 '23: 15.2M Q2 '23: 16.8M Q3 '23: 16.9M Q4 '23: 6.7M Q1 '24: 6.6M Q2 '24: 7.6M Q3 '24: 7.5M Q4 '24: 9.6M Q1 '25: 9M Q2 '25: 9.4M Q3 '25: 9.1M Q4 '25: 7.5M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Gross Profit TTM

0 2M 4M 6M Q4 '23: 2.9M Q1 '24: 2.7M Q2 '24: 2.7M Q3 '24: 2.8M Q4 '24: 4.7M Q1 '25: 4.3M Q2 '25: 4.4M Q3 '25: 4.1M Q4 '25: 2.6M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '19: -10.2M Q1 '20: -8.6M Q2 '20: -6.3M Q3 '20: -6.2M Q4 '20: -5.7M Q1 '21: -5.8M Q2 '21: -6.5M Q3 '21: -6.8M Q4 '21: -8.7M Q1 '22: -10.2M Q2 '22: -12.7M Q3 '22: -14.4M Q4 '23: -8.5M Q1 '24: -6.1M Q2 '24: -8.7M Q3 '24: -13.9M Q4 '24: -18.3M Q1 '25: -20.1M Q2 '25: -18.7M Q3 '25: -14.7M Q4 '25: -10.7M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '25 Q4 '25

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '19: -6M Q1 '20: -352K Q2 '20: -4M Q3 '20: -4.8M Q4 '20: -5.1M Q1 '21: -7.4M Q2 '21: -6M Q3 '21: -6.8M Q4 '21: -8.4M Q1 '22: -9.6M Q2 '22: -11.7M Q3 '22: -13.2M Q4 '23: -3.5M Q1 '24: -631K Q2 '24: -1.2M Q3 '24: -6.2M Q4 '24: -15.3M Q1 '25: -17.6M Q2 '25: -18.8M Q3 '25: -14.9M Q4 '25: -10.4M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '25 Q4 '25

Cost of Revenue TTM

0 3M 6M 9M Q1 '19: 2.1M Q2 '19: 2M Q3 '19: 1.5M Q4 '19: 410K Q1 '20: 1.3M Q2 '20: 1.2M Q3 '20: 1.2M Q4 '20: 2.3M Q1 '21: 1.5M Q2 '21: 1.5M Q3 '21: 1.5M Q4 '21: 90K Q1 '22: 140K Q2 '22: 141K Q3 '22: 124K Q4 '22: 6M Q1 '23: 6M Q2 '23: 6.5M Q3 '23: 7.7M Q4 '23: 2.8M Q1 '24: 4M Q2 '24: 4.9M Q3 '24: 4.7M Q4 '24: 4.9M Q1 '25: 4.8M Q2 '25: 5M Q3 '25: 5M Q4 '25: 4.9M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q4 '19: -10.7M Q1 '20: -10.2M Q2 '20: -10.4M Q3 '20: -9.6M Q4 '20: -4.1M Q1 '21: -2.7M Q2 '21: -4M Q3 '21: -3.6M Q4 '21: -8.6M Q1 '22: -9M Q2 '22: -10.2M Q3 '22: -12.7M Q4 '22: 5.2M Q1 '23: 2.6M Q2 '23: 6.7M Q3 '23: 10.8M Q4 '23: -2.6M Q1 '24: -901K Q2 '24: -1.5M Q3 '24: -9.4M Q4 '24: -14.5M Q1 '25: -14M Q2 '25: -17.1M Q3 '25: -10M Q4 '25: -8.5M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q4 '21: -8.6M Q1 '22: -9M Q2 '22: -10.3M Q3 '22: -12.7M Q4 '22: 4.9M Q1 '23: 2.3M Q2 '23: 6.4M Q3 '23: 10.4M Q4 '23: -3.3M Q1 '24: -2.2M Q2 '24: -2.8M Q3 '24: -10.8M Q4 '24: -15.7M Q1 '25: -15.3M Q2 '25: -18.2M Q3 '25: -11M Q4 '25: -9.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '18: 16.4M Q3 '18: 16.4M Q1 '19: 16.4M Q2 '19: 17.3M Q3 '19: 16.9M Q1 '20: 21.9M Q2 '20: 23.5M Q3 '20: 56.2M Q1 '21: 95.4M Q2 '21: 4.8M Q3 '21: 4.9M Q1 '22: 121.4M Q2 '22: 4.9M Q3 '22: 4.9M Q1 '23: 1.2M Q2 '23: 1.8M Q3 '23: 1.8M Q1 '24: 1.8M Q2 '24: 2.2M Q3 '24: 3.1M Q1 '25: 3.1M Q2 '25: 3.2M Q3 '25: 3.2M Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '19: -0.35 Q1 '20: -0.01 Q2 '20: -0.17 Q3 '20: -0.17 Q4 '20: -3.13 Q1 '21: -3.19 Q2 '21: -3.47 Q3 '21: -3.05 Q4 '21: -0.66 Q1 '22: -0.66 Q2 '22: -1.10 Q3 '22: -2.20 Q4 '24: -5.60 Q1 '25: -6.00 Q2 '25: -6.21 Q3 '25: -4.93 Q4 '25: -3.26 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.